Trials / Completed
CompletedNCT00706706
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 105 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib Malate (SU011248) | Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg. |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2008-06-27
- Last updated
- 2013-01-18
- Results posted
- 2012-12-20
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00706706. Inclusion in this directory is not an endorsement.